Lv4
423 积分 2021-07-29 加入
Exploiting the folate receptor α in oncology
2小时前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
2小时前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
2小时前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
4个月前
已完结
Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy
5个月前
已完结
[Consensus on the molecular residual disease testing in solid tumor]
5个月前
已完结
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
5个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
6个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
6个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
7个月前
已关闭
皖公网安备34019202002308
